ADCETRIS

The impact of Clay Siegall in Seattle Genetics

The presence of the Seattle Genetics makes the world a better place to live in. In the recent time’s research conducted by organizations such as the Seattle Genetics has brought a scientific breakthrough in the combating diseases such as cancer and others. At the entrance of Bothell’s Cascade Business Park, you will be welcomed by a green triangular sculpture which is made of Lego bricks which merely communicates a version of the human antibody. From its time of incorporation, the company core activities are manipulating, studying and final packaging of the drugs. Notably, the company does not only deal with the development of antibodies, but its efficiency is a result of the providing therapy. Seattle Genetics has a market value of more than 10 billion dollars and more than 900 employees, and as a result, it is considered as the most significant biotech in Washington. In future, the company aims at joining the club of few elite institutions which have graduated from biotech to large pharmacy.

To reach the above milestone the company has invested significantly in research and marketing and will add more than 200 employees in its labor force. One of the trademark drugs for the company is Adcetris which provides treatment for the Hodgkin lymphoma. According to the Clay Siegall the CEO, the company, is emerging as multiproduct, global and oncology.

Clay Siegall is among the founders of Seattle Genetics which was founded in 1988.As the CEO and the chairman of the board, the company has experienced robust growth from being a startup company to the best biotech in Washington. Under his leadership, the company has accomplished a milestone in breakthrough research which includes drugs such as Adcetris which received a clean bill of health from the U.S government. When it comes to raising funds for the organization, Clay Siegall has managed to mobilize more than $675 million through the initiative of the public and private agreement. Back in the year 2001, he leads the company to initial public offering.

Clay holds a bachelor degree in Zoology from the University of Maryland, and he is a recipient of Ph.D. IN Genetics from George Washington University.Despite being a CEO of Seattle Genetics, he is a board member of institutions such as Alder Biopharmaceuticals, Mirma Therapeutics, Fred Hutchinson Cancer Research Center among others. The leadership qualities of Clay has played a significant impact on the growth of the Seattle Genetics.

Tags :